Table 2

Patient demographics and baseline clinical characteristics of patients randomized to receive either ART plus nutritional supplement (NS) or ART alone (Control) for 6 months
Characteristics Nutritional supplement Control p value Completers* Non-completers* p value
n = 19 n = 19 n = 26 n = 12
Gender – Male n,% 6 (31.6%) 7 (36.8%) 0.732 8 (30.8%) 5 (41.7%) 0.510
Age (years) Median (IQR) 37 (32 – 42) 34 (30 – 43) 0.612 37 (32 – 42) 34.5 (31.5 – 42.5) 0.505
Employed n,% 14 (73.7%) 11 (57.9%) 0.456 15 (57.7%) 10 (83.3%) 0.122
Education
  < Grade 8 n,% 2 (10.5%) 1 (5.3%) 0.222 1 (3.8%) 1 (8.3%) 0.114
  ≥ Grade 8 n,% 17 (89.5%) 18 (94.7%) 24 (92.3%) 11 (91.7%)
Self-reported weight loss (kg) Median (IQR) 5 (3 – 5) 5 (2 – 9) 0.094 5 (3 – 8) 5 (4 – 7) 0.356
Body mass index (BMI; kg/m2) Median (IQR) 20.4 (18.0 – 22.4) 19.3 (18.4 – 21.3) 0.197 20.2 (17.6 – 21.7) 19.7 (18.0 – 21.7) 0.842
  < 18.5 kg/m2 n,% 6 (31.6%) 4 (21.1%) 0.461 6 (23.1%) 1 (8.3%) 0.234
Fat (kg) Median (IQR) 10.6 (10.0 – 17.7) 11.1 (5.5 – 15.5) 0.560 11.1 (9.1 – 15.9) 10.5 (8.6 – 12.0) 0.791
Systolic blood pressure (mmHg) Median (IQR) 104 (90 – 125) 111 (107 – 127) 0.079 111 (102 – 127) 107 (95 – 120) 0.354
Diastolic blood pressure (mmHg) Median (IQR) 69 (46 – 76) 71 (66 – 84) 0.209 71 (66 – 87) 68 (56 – 75) 0.209
WHO stage III/IV n,% 4/12 (33.3%) 7/16 (43.8%) 0.611 7/19 (36.8%) 4/9 (44.4%) 0.966
ART regimen
  TDF/3TC/EFV n,% 14 (73.7%) 14 (73.7%) 1.000 22 (84.6%) 6 (50.0%) 0.031
  TDF/3TC/NVP n,% 1 (5.3%) 1 (5.3%) - 2 (16.7%)
  d4T/3TC/EFV n,% 4 (21.0%) 4 (21.0%) 4 (15.4%) 4 (33.3%)
CD4 cells/mm3 Median (IQR) 60 (12 – 105) 107 (63 – 165) 0.149 86 (24 – 125) 99 (70 – 121) 0.405
  ≤ 50 n,% 8 (42.1%) 4 (21.0%) 0.027 10 (38.5%) 2 (16.7%) 0.152
  51 – 100 n,% 5 (26.3%) 5 (26.4%) 6 (23.0%) 4 (33.3%)
  101 – 200 n,% 6 (31.6%) 6 (31.6%) 6 (23.0%) 6 (50.0%)
  > 201 – 350 n,% 0 (0.0%) 4 (21.0%) 4 (15.5%) 0 (0.0%)
Hemoglobin (g/dL) Median (IQR) 10.3 (9.0 – 11.3) 13.1 (11.1 – 14.7) 0.001 11.6 (10.3 – 13.6) 11.0 (9.4 – 12.6) 0.294
  < 10 g/dL n,% 9 (47.4%) 1 (5.3%) 0.009 5 (19.2%) 5 (41.7%) 0.144
Viral load (log10) Median (IQR) 5.4 (4.7 – 5.8) 5.6 (5.4 – 6.0) 0.042 5.5 (4.7 – 5.8) 5.2 (4.9 – 5.6) 0.851
Mean cell volume (fL) Median (IQR) 85.0 (78.4 – 98.9) 91.3 (84.0 – 94.8) 0.090 90.1 (81.5 – 94.6) 83.2 (78.3 – 88.0) 0.096
TB at initiation n,% 2 (10.5%) 0 (0.0%) 0.157 1 (4.4%) 1 (8.3%) 0.629
Alcohol (current/history) n,% 8 (42.1%) 4 (21.1%) 0.045 8 (30.8%) 4 (33.3%) 0.846
Smoking (current/history) n,% 5/19 (26.3%) 1/18 (5.6%) 0.063 3/26 (11.5%) 2/11 (18.2%) 0.409

*Patient demographics and baseline clinical characteristics of those that completed (completers) and those that did not complete the 6 month follow-up (non-completers) were compared.

Evans et al.

Evans et al. Nutrition Journal 2013 12:111   doi:10.1186/1475-2891-12-111

Open Data